TEST:

AMBLor®

The e-DAM study demonstrates expert consensus that AMBLor™ could augment clinical decision making at key junctures in the cMM care pathway by refining SLNB selection, rationalising adjuvant therapy and imaging, and reducing follow-up burdens - enhancing personalised care, whilst alleviating service pressures.

However, its predictive accuracy remains limited. This is due to the possible influence of additional prognostic factors and, importantly, to the absence of standardized protocols for MAD measurement, including imaging techniques and anatomical reference points.

"AMLo Biosciences said Tuesday that it has received UK Conformity Assessed (UKCA) marking for its AMBLor test for identifying early-stage melanomas at low risk of progression.."